Senesco Technologies

We are engaged in the research and development of genetic technologies to improve commercial agriculture and to treat major medical conditions in humans. Our platform technology is based on the identification and characterization of specific genes that are responsible for plant cell death (senescence) and for programmed cell death in humans (apoptosis). We are developing our technologies to address multiple opportunities within the global commercial agriculture industry, including extending the shelf life of perishable plant products, producing larger and leafier crops, increasing crop yields and reducing the harmful effects of environmental stresses, like drought. We are also researching applications of our technologies which may address the many human diseases associated with suppressed or premature apoptosis, including cancer, glaucoma, and cardiovascular disease.

Contact Details: 303 George St., Suite 420 New Brunswick New Jersey 08901 United States of America Tel: 732.296.8400 Fax: 732.296.9292 Email: info@senesco.com WWW: www.senesco.com/

Loading...

Press Releases on Senesco Technologies:
Senesco Technologies Reports First Quarter Fiscal 2010 Financial Results	17th November, 2009	Senesco Technologies, Inc.	-- Richard Dondero, Vice President of Research & Development at Senesco, delivered the Company's corporate presentation at the 11th Annual Rodman & Renshaw Healthcare
Senesco Technologies, Inc. Announces Management Change	16th November, 2009	Senesco Technologies, Inc.	NEW BRUNSWICK, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that, on November 16, 2009, Bruce C.
Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference	12th November, 2009	Senesco Technologies, Inc.	NEW BRUNSWICK, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced today that Catherine Taylor, one of the
Certain Senesco Insiders to Purchase Senesco Securities Held by Stanford Venture Capital Holdings and by Stanford International Bank	9th November, 2009	Senesco Technologies, Inc.	NEW BRUNSWICK, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) reported today that certain insiders of Senesco
Senesco Technologies Receives Notice of Non Compliance From AMEX	4th November, 2009	Senesco Technologies, Inc.	NEW BRUNSWICK, N.J., Nov. 4 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. (the "Company") (NYSE Amex: SNT) has received a notice from the NYSE Amex LLC ("NYSE") providing

BioNews Results for Senesco Technologies:
Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor	News-Medical.Net:  Nov 18 2009 8:58PM Matching: senesco technologies
Senesco Technologies, Inc. Announces Management Change	KOTA Territory News:  Nov 17 2009 1:56PM Matching: senesco technologies
Senesco Technologies, Inc. Announces Management Change	Montana's News Station:  Nov 17 2009 7:25AM Matching: senesco technologies
Senesco Technologies, Inc. Announces Management Change	Pharma Live:  Nov 17 2009 12:42AM Matching: senesco technologies
Senesco Technologies Reports First Quarter Fiscal 2010 Financial Results	KOTA Territory News:  Nov 17 2009 1:57PM Matching: senesco technologies
Promote your company here: BioNewsCast - Press Release Distribution	→View more Senesco Technologies news.

Senesco Technologies Patents:
US Patent No.	Title
7588888	DNA encoding a plant deoxyhypusine synthase, a plant eukaryotic initiation factor 5A, transgenic plants and a method for controlling senescence programmed and cell death in plants
7358418	Isoforms of eIF-5A: senescence-induced eLF5A; wounding-induced eIF-4A; growth eIF-5A; and DHS
7217517	Nucleic acids, polypeptides, and methods for modulating apoptosis
7166467	Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
6867237	DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans
→View more Senesco Technologies patents.

Senesco Technologies (SNT) Financial information Links from Barchart
SNT Quote from from Barchart.com
SNT Chart from from Barchart.com
SNT Profile from from Barchart.com
SNT Opinion from from Barchart.com
→View more Senesco Technologies finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 278 times since April 2007, the link to the organisation's website has been followed 43 times

Search for more companies in New Brunswick

Search for more companies in New Jersey

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Senesco Technologies